Zoetis announced the launch of Vanguard Recombishield

Zoetis announced the U.S. launch of Vanguard® Recombishield™ (Bordetella bronchiseptica vaccine), a new injectable vaccine to protect against Bordetella bronchiseptica, also known as kennel cough. Licensed by the U.S. Department of Agriculture (USDA) on March 4, 2025, Recombishield is the first and only vaccine for dogs with pertactin protein for an optimized immune response. This innovation in Bordetella protection uses recombinant technology to provide a comfortable immunization experience for the pet, with minimal pain, swelling, stinging and sensitivity.

“Every dog is different, and intranasal or oral delivery may not be the right fit for every dog to protect against kennel cough,” said Tara Bidgood, DVM, PhD, DACVCP, Vice President, Head of U.S. Veterinary Professional Services and Medical Affairs, Petcare at Zoetis. “However, given how quickly Bordetella can spread, it is important to ensure dogs are fully protected from this potentially serious bacterial infection. At Zoetis, we are committed to innovating to advance pet health. With Vanguard Recombishield, we are proud to be the only company to offer veterinarians and pet parents a full suite of innovative administration options, ensuring every pet receives optimized protection regardless of their specific needs or temperament.”

Recombishield is now available in the United States for order directly from Zoetis. Veterinarians and pet health professionals can also purchase Recombishield through their preferred U.S. distributor partner or through Vetcove.

Visit https://www.zoetisus.com/products/dogs/vanguard/vanguard-recombishield to learn more about Vanguard Recombishield.